-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analyzing Dermata Therapeutics (NASDAQ:DRMA) and Selecta Biosciences (NASDAQ:SELB)
Analyzing Dermata Therapeutics (NASDAQ:DRMA) and Selecta Biosciences (NASDAQ:SELB)
Dermata Therapeutics (NASDAQ:DRMA – Get Rating) and Selecta Biosciences (NASDAQ:SELB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Profitability
This table compares Dermata Therapeutics and Selecta Biosciences' net margins, return on equity and return on assets.
Get Dermata Therapeutics alerts:Net Margins | Return on Equity | Return on Assets | |
Dermata Therapeutics | N/A | -119.62% | -103.21% |
Selecta Biosciences | 33.67% | 32.84% | 12.35% |
Earnings & Valuation
This table compares Dermata Therapeutics and Selecta Biosciences' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Dermata Therapeutics | N/A | N/A | -$7.90 million | N/A | N/A |
Selecta Biosciences | $85.08 million | 3.09 | -$25.69 million | $0.12 | 14.33 |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Dermata Therapeutics and Selecta Biosciences, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Dermata Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Selecta Biosciences | 0 | 0 | 3 | 0 | 3.00 |
Dermata Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 249.65%. Selecta Biosciences has a consensus target price of $5.33, indicating a potential upside of 210.08%. Given Dermata Therapeutics' higher possible upside, equities research analysts plainly believe Dermata Therapeutics is more favorable than Selecta Biosciences.
Institutional and Insider Ownership
1.6% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of Selecta Biosciences shares are owned by institutional investors. 36.3% of Dermata Therapeutics shares are owned by insiders. Comparatively, 30.5% of Selecta Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Dermata Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Selecta Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
Summary
Selecta Biosciences beats Dermata Therapeutics on 7 of the 10 factors compared between the two stocks.
About Dermata Therapeutics
(Get Rating)
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
About Selecta Biosciences
(Get Rating)
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Dermata Therapeutics (NASDAQ:DRMA – Get Rating) and Selecta Biosciences (NASDAQ:SELB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
皮玛塔治疗(纳斯达克:DRMA-GET评级)和选择生物科学(纳斯达克:SELB-GET评级)都是小盘医疗公司,但哪只股票更优?我们将根据两家公司的股息、收益、风险、估值、分析师建议、盈利能力和机构持股情况对它们进行比较。
Profitability
盈利能力
This table compares Dermata Therapeutics and Selecta Biosciences' net margins, return on equity and return on assets.
此表比较了Dermata Treeutics和Selecta Biosciences的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Dermata Therapeutics | N/A | -119.62% | -103.21% |
Selecta Biosciences | 33.67% | 32.84% | 12.35% |
净利润率 | 股本回报率 | 资产回报率 | |
皮肤治疗学 | 不适用 | -119.62% | -103.21% |
精选生物科学 | 33.67% | 32.84% | 12.35% |
Earnings & Valuation
收益与估值
This table compares Dermata Therapeutics and Selecta Biosciences' revenue, earnings per share and valuation.
该表比较了德玛塔治疗公司和Selecta生物科学公司的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Dermata Therapeutics | N/A | N/A | -$7.90 million | N/A | N/A |
Selecta Biosciences | $85.08 million | 3.09 | -$25.69 million | $0.12 | 14.33 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
皮肤治疗学 | 不适用 | 不适用 | -790万元 | 不适用 | 不适用 |
精选生物科学 | 8,508万美元 | 3.09 | -2,569万元 | $0.12 | 14.33 |
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and price targets for Dermata Therapeutics and Selecta Biosciences, as provided by MarketBeat.com.
这是由MarketBeat.com提供的Dermata Treateutics和Selecta Biosciences最近的评级和目标价细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Dermata Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Selecta Biosciences | 0 | 0 | 3 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
皮肤治疗学 | 0 | 0 | 1 | 0 | 3.00 |
精选生物科学 | 0 | 0 | 3 | 0 | 3.00 |
Dermata Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 249.65%. Selecta Biosciences has a consensus target price of $5.33, indicating a potential upside of 210.08%. Given Dermata Therapeutics' higher possible upside, equities research analysts plainly believe Dermata Therapeutics is more favorable than Selecta Biosciences.
德玛塔治疗公司目前的共识目标价为1.00美元,这表明潜在的上涨幅度为249.65%。Selecta Biosciences的共识目标价为5.33美元,表明潜在上涨210.08%。考虑到Dermata治疗公司更高的可能上行空间,股票研究分析师显然认为Dermata治疗公司比Selecta生物科学公司更有利。
Institutional and Insider Ownership
机构和内部人持股
1.6% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of Selecta Biosciences shares are owned by institutional investors. 36.3% of Dermata Therapeutics shares are owned by insiders. Comparatively, 30.5% of Selecta Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
德玛塔治疗公司1.6%的股份由机构投资者持有。相比之下,Selecta Biosciences 40.3%的股份由机构投资者持有。德玛塔治疗公司36.3%的股份由内部人士持有。相比之下,Selecta Biosciences 30.5%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一家公司有望实现长期增长。
Risk and Volatility
风险和波动性
Dermata Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Selecta Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
德玛塔治疗公司的贝塔指数为0.91,这意味着其股价的波动性比标准普尔500指数低9%。相比之下,Selecta Biosciences的贝塔系数为0.96,这意味着其股价的波动性比标准普尔500指数低4%。
Summary
摘要
Selecta Biosciences beats Dermata Therapeutics on 7 of the 10 factors compared between the two stocks.
在两只股票之间的10个因素中,有7个因素Selecta Biosciences超过了Dermata Treateutics。
About Dermata Therapeutics
关于皮肤治疗学
(Get Rating)
(获取评级)
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
皮玛塔治疗公司是一家临床阶段的生物技术公司,专注于识别、开发和商业化治疗医疗和美容皮肤疾病的候选药物。该公司的主要候选产品是DMT310,它已经完成了治疗中到重度痤疮的IIb阶段临床试验;以及用于轻到中度牛皮癣的Ib阶段概念验证(POC)试验,以及治疗中到重度酒渣鼻的第二阶段临床试验。该公司还在开发DMT410,该产品已经完成了Ib期POC试验,用于治疗多汗症和美容条件。该公司成立于2014年,总部位于加利福尼亚州圣地亚哥。
About Selecta Biosciences
关于SELECTA生物科学
(Get Rating)
(获取评级)
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
SELECTA生物科学公司是一家临床阶段的生物制药公司,从事治疗和预防人类疾病的纳米颗粒免疫调节药物的研究和开发。它生产用于免疫耐受和免疫刺激的合成疫苗颗粒(SVP)平台。该公司的专利流水线包括支持SVP的酶、肿瘤学和基因疗法。该公司由奥米德·C·法罗克扎德、小罗伯特·S·兰格和乌尔里希·冯·安德里安于2007年创立,总部设在马萨诸塞州沃特敦。
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受皮肤病治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Dermata Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧